SCHEMBL8187464

SCHEMBL8187464

O=C(O)c1nc2scc(-c3cnccn3)c2c(=O)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
KMT2A Q03164 4/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ALDH1A1 P00352 6/20 0.39
MAPT P10636 3/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.38
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
LMNA P02545 1/20 0.35
KRAS P01116 1/20 0.35
TNF P01375 1/20 0.35
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8200546 0.89 KDM4E (0.37) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL8202645 0.83 KDM4E (0.51) KDM4EKMT2AALDH1A1MAPTPOLB
SCHEMBL5062988 0.81 KMT2A (0.55) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL8202655 0.80 CDC7 (0.38) KDM4EKMT2AALDH1A1MAPTPOLB
SCHEMBL8204571 0.80 KMT2A (0.58) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL13343733 0.78 ALDH1A1 (0.43) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL8198010 0.73 KMT2A (0.68) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL8197798 0.73 ALDH1A1 (0.45) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL8199920 0.72 ALDH1A1 (0.67) KDM4EKMT2ASENP8SENP7SENP6
SCHEMBL8195968 0.72 ALDH1A1 (0.61) KDM4EKMT2ASENP8SENP7SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 KDM4E 1572/4885KMT2A 2275/4885SENP8 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.